Smith+Nephew Reports Strong FY2025 Results, Completes 12-Point Plan, and Initiates New Growth Strategy
SNN sits 47% above its 52-week low of $23.91.
Summary
Smith+Nephew reported strong full-year 2025 results, completed its 12-Point Plan, and launched a new RISE strategy with positive 2026 guidance, including a $500 million share buyback and dividend increase.
Key Events · Earnings and Guidance · SNN
-
Full Year 2025 Financial Performance
Reported 6.1% revenue growth to $6.16 billion, 20.7% operating profit increase to $794 million, and a 52.5% surge in free cash flow to $840 million, exceeding targets.
-
Strategic Transformation Completed
Successfully concluded the 12-Point Plan, strengthening operational foundations and launching the new RISE strategy with ambitious 2028 financial targets for accelerated growth and returns.
-
Positive 2026 Outlook
Forecasts underlying revenue growth of approximately 6% and trading profit of around $1.3 billion, with adjusted ROIC expected to exceed 10%.
-
Shareholder Returns
Completed a $500 million share buyback in H2 2025 and increased the full-year dividend by 4.3% to 39.1¢ per share.
Analysis · SNN · Industrial Applications And Services
This 6-K details Smith+Nephew's robust financial performance for the full year 2025, exceeding revenue, profitability, and cash generation targets. The company successfully completed its 12-Point Plan, transforming into a stronger business, and launched its new RISE strategy with ambitious 2028 financial targets. The positive 2026 outlook, including accelerated revenue growth and increased trading profit, coupled with a significant $500 million share buyback and a dividend increase, signals strong operational momentum and a commitment to shareholder returns. Investors should note the long-term strategic direction and the expected accretion from the Integrity Orthopaedics acquisition by 2028.
At the time of this filing, SNN was trading at $35.13 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $15.7B. The 52-week trading range was $23.91 to $38.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.